Topiroxostat
As of the edition of 20 October 2026, Topiroxostat is a small molecule: marketed, first approved in 2013 (JP); acts on XDH.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Topiloric
- First approved
- 28 June 2013 (JP)
- Approvals on record
- 3 in 1 region
- Holder of the most recent approval
- Senwa Kegaku Kenkyushp; 3 holders in all
- Registered trials
- 1, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| XDH | Xanthine dehydrogenase/oxidase [Includes: Xanthine dehydrogenase | P47989 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanwa Kagaku Kenkyusho | Applicant | 2013 to now |